Zoya Technologies Launches Clinical AI Terminal Engineered to Operate Without Internet Connectivity
17.6.2026 10:00:00 EEST | Business Wire | Press release
Almost every digital health system assumes the internet will be there. Zoya Technologies today launched the ZoyeMed 3.0 Resilience Edition, a clinical AI terminal engineered to deliver a complete medical episode without an internet connection at any stage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617381037/en/
The ZoyeMed 3.0 Resilience Edition - a fully standalone clinical AI terminal engineered to operate without internet connectivity, integrating point-of-care diagnostics, examination tools, and on-device AI in a single 5-square-metre footprint (Photo: AETOSWire)
Continuity of care is the first casualty of infrastructure disruption. Disasters, grid instability, and remote deployments routinely sever the connectivity that cloud-dependent systems require - when clinical capacity is most needed.
The Resilience Edition is a fully standalone configuration of ZoyeMed 3.0. The complete Longitudinal Multimodal Model and Zoyel.health clinical suite are resident on the device, executing locally on the company’s proprietary Amygdala edge AI engine. A terminal can operate indefinitely without a network connection.
“Clinical intelligence should remain available to the patient and the clinician regardless of the state of the network around them,” said Dr. Syed Sabahat Azim, Chief Executive Officer of Zoya Technologies. “We have removed the cloud from the critical path of care - not as a feature, but as the architecture.”
In a 5-square-metre footprint, the Resilience Edition delivers a complete medical episode in under 30 minutes. It integrates 12-lead ECG, digital stethoscopy, spirometry, dermatoscope, otoscope, fetal Doppler, a 12-camera telepresence array, and biochemistry, haematology, and immunoassay analysers supporting 120+ point-of-care tests. It operates in three modes: doctor-run, nurse-managed with remote clinician sign-off, and autonomous screening.
The Resilience Edition builds on existing ZoyeMed deployments across multiple regions, in commercial service since 2025. It is a human-in-the-loop system; final clinical decisions remain under the authority of a licensed clinician.
Zoya Technologies has also deployed an immutable audit trail across the platform - hash-chained, append-only records of every clinical action, particularly relevant in disconnected environments.
The Resilience Edition is available through Zoya Technologies’ authorised distribution partners. Product imagery and the clinical white paper are available on request.
About Zoya Technologies LLC
Zoya Technologies LLC is a deep-technology infrastructure company focused on building edge-native systems for real-world service delivery at scale. The company develops physically grounded, autonomous systems that integrate sensing, safety, and longitudinal intelligence, with healthcare as its first deployed domain.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20260617381037/en/
Contacts
Sanket Santra
communications@zoyel.one
+97142266599
www.zoyel.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.zoyel.com&e
sheet=54553362&newsitemid=20260617381037&lan=en-US&anchor=www.zoyel.com&index=2&
md5=ed85aeef68a4c55e61ffef900432fd21
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom